INMED PHARMACEUTICALS INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- INMED PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2022-12-31 was $53.00.
- INMED PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $419.00.
- INMED PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2023 was $646.00.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-06-30 | $175.00 S-4 · filed 2026-07-02 | |
| 2023-06-30 | $646.00 10-K · filed 2024-09-30 | |
| 2022-12-31 | $53.00 10-Q · filed 2024-02-13 | |
| 2022-09-30 | $419.00 10-Q · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |